Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Swann in a report issued on Wednesday, The Fly reports. They presently have a $125.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $115.00. Leerink Swann’s target price suggests a potential upside of 33.76% from the stock’s previous close.

A number of other research analysts also recently issued reports on the stock. Royal Bank Of Canada set a $88.00 target price on shares of Puma Biotechnology and gave the company a “hold” rating in a research report on Monday. J P Morgan Chase & Co reiterated a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday. Citigroup Inc. restated a “buy” rating and set a $114.00 price objective on shares of Puma Biotechnology in a report on Tuesday. Stifel Nicolaus restated a “buy” rating and set a $118.00 price target (up previously from $105.00) on shares of Puma Biotechnology in a research report on Tuesday. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $118.00 price objective (up from $90.00) on shares of Puma Biotechnology in a report on Tuesday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $95.75.

Shares of Puma Biotechnology (NYSE:PBYI) opened at 93.45 on Wednesday. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $97.15. The company has a 50 day moving average of $83.89 and a 200 day moving average of $49.69. The firm’s market cap is $3.45 billion. Puma Biotechnology also saw some unusual options trading activity on Tuesday. Investors bought 12,110 put options on the company. This is an increase of approximately 868% compared to the average daily volume of 1,251 put options.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. On average, equities analysts forecast that Puma Biotechnology will post ($8.40) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Puma Biotechnology Inc (NYSE:PBYI) Rating Reiterated by Leerink Swann” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/07/19/puma-biotechnology-inc-nysepbyi-rating-reiterated-by-leerink-swann.html.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 507,128 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $87.84, for a total value of $44,546,123.52. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Richard Paul Bryce sold 5,000 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $87.10, for a total value of $435,500.00. Following the completion of the transaction, the senior vice president now directly owns 34,237 shares in the company, valued at $2,982,042.70. The disclosure for this sale can be found here. Insiders have sold a total of 1,995,088 shares of company stock valued at $157,988,613 over the last three months. 22.70% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Camber Capital Management LLC acquired a new stake in Puma Biotechnology during the first quarter worth $24,180,000. Redmile Group LLC boosted its position in Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock valued at $64,185,000 after buying an additional 435,274 shares during the last quarter. Emerald Advisers Inc. PA purchased a new position in Puma Biotechnology during the first quarter valued at $14,110,000. Emerald Mutual Fund Advisers Trust purchased a new position in Puma Biotechnology during the first quarter valued at $9,702,000. Finally, Norges Bank purchased a new position in Puma Biotechnology during the fourth quarter valued at $7,693,000. 80.98% of the stock is currently owned by institutional investors and hedge funds.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

The Fly

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.